D. Corti

Broadly neutralizing antibodies against emerging delta-coronaviruses

The paper isolates two human monoclonal antibodies that broadly neutralize PDCoV variants and identifies their mechanism of action.

A broadly generalizable stabilization strategy for sarbecovirus fusion machinery vaccines

This paper develops a stabilization strategy for sarbecovirus fusion machinery vaccines, showing broad reactivity and protection against SARS-CoV-2 variants.

Broad receptor tropism and immunogenicity of a clade 3 sarbecovirus

This study characterizes the receptor tropism and antigenicity of a clade 3 sarbecovirus, identifying broad ACE2 usage and cross-neutralizing antibodies with implications for vaccine design.

Natural heteroclitic-like peptides are generated by SARS-CoV-2 mutations

The paper shows that SARS-CoV-2 mutations can create new CD8 T cell epitopes, enhancing immune responses in some individuals with weak CD8 T cell reactivity.

Maturation of SARS-CoV-2 Spike-specific memory B cells drives resilience to viral escape

The paper examines the kinetics, avidity, and cross-reactivity of SARS-CoV-2-specific memory B cells and antibodies in infected and vaccinated individuals over 16 months, finding that MBC maturation enhances resilience to viral escape.

The potent broadly neutralizing antibody VIR-3434 controls Hepatitis B and D Virus infection and reduces HBsAg in humanized mice

This paper identifies a potent anti-HBs mAb, VIR-3434, that neutralizes HBV and HDV and reduces HBsAg and viremia in human liver-chimeric mice.

ACE2 engagement exposes the fusion peptide to pan-coronavirus neutralizing antibodies

The paper identifies monoclonal antibodies that neutralize multiple coronaviruses by targeting the fusion peptide, which becomes exposed upon ACE2 engagement.

Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains

This study evaluates the effectiveness of S309 and AZD7442 monoclonal antibodies against Omicron variants in mice, showing reduced lung infection despite decreased neutralization in vitro.

Omicron BA.1 and BA.2 neutralizing activity elicited by a comprehensive panel of human vaccines

This study evaluates neutralizing activity against Omicron BA.1 and BA.2 variants elicited by various vaccines and finds that booster doses enhance neutralizing titers and breadth across all vaccine platforms.

Shifting mutational constraints in the SARS-CoV-2 receptor-binding domain during viral evolution

The paper analyzes epistatic shifts in SARS-CoV-2 RBD mutations across variants to understand how they influence ACE2 binding and future evolution.

Structural changes in the SARS-CoV-2 spike E406W mutant escaping a clinical monoclonal antibody cocktail

The paper examines structural changes in the SARS-CoV-2 spike E406W mutant that reduce neutralization by a monoclonal antibody cocktail and alters epitope recognition.

Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement

This study determines the structural basis of SARS-CoV-2 Omicron's immune evasion and receptor engagement through cryo-EM and X-ray crystal structures of the spike and RBD bound to antibodies and ACE2.

SARS-CoV-2 spike conformation determines plasma neutralizing activity

This study shows that vaccines encoding a prefusion-stabilized SARS-CoV-2 spike protein induce higher neutralizing antibody titers and better variant cross-neutralization compared to other vaccines or infection.

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by several therapeutic monoclonal antibodies

This study evaluates the neutralization of the SARS-CoV-2 Omicron variant by therapeutic monoclonal antibodies and finds that several lose efficacy against the variant.

Structure of the rabies virus glycoprotein trimer bound to a pre-fusion specific neutralizing antibody

The paper reports the cryo-EM structure of pre-fusion rabies virus glycoprotein bound to the neutralizing antibody RVA122, revealing its trimeric interface and stabilization mechanism.

Structure, receptor recognition and antigenicity of the human coronavirus CCoV-HuPn-2018 spike glycoprotein

The paper determines the structure of the CCoV-HuPn-2018 spike glycoprotein, identifies its receptor, and shows cross-neutralizing antibodies against related coronaviruses.

Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry

This study identifies a broadly neutralizing antibody against sarbecoviruses that targets the ACE2 binding site and shows high resistance to escape mutations.

A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy

This study compares antibody responses to early SARS-CoV-2 isolates and the B.1.351 variant, finding shifts in immunodominance hierarchy within the spike receptor-binding domain.

Molecular basis of immune evasion by the delta and kappa SARS-CoV-2 variants

This study investigates how delta and kappa SARS-CoV-2 variants evade immune responses by altering antigenic sites and reducing ACE2 binding affinity.

Extremely potent human monoclonal antibodies for the prophylaxis and therapy of Tetanus

This study identifies two human monoclonal antibodies with high neutralizing activity against tetanus neurotoxin, showing potential for both prophylaxis and therapy.

Heparin protects human neural progenitor cells from Zika Virus-induced cell death and preserves their differentiation into mature neural-glia cells

Membrane lectins enhance SARS-CoV-2 infection and influence the neutralizing activity of different classes of antibodies

This study identifies membrane lectins that enhance SARS-CoV-2 infection and show how different antibodies neutralize infection through distinct mechanisms.

SARS-CoV-2 immune evasion by variant B.1.427/B.1.429

This study evaluates how the B.1.427/B.1.429 SARS-CoV-2 variant evades neutralizing antibodies through mutations in the RBD and NTD, showing reduced neutralization by both vaccine-induced and infection-derived antibodies.

The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2

This paper evaluates the in vitro and in vivo efficacy of dual-action monoclonal antibodies VIR-7831 and VIR-7832 against SARS-CoV-2, showing potent neutralization and reduced viral load in a hamster model.

N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2

The paper identifies a conserved antigenic supersite on the SARS-CoV-2 N-terminal domain recognized by neutralizing antibodies and shows its vulnerability to mutations in variants.

Closing coronavirus spike glycoproteins by structure-guided design

This paper designs a stabilized SARS-CoV-2 spike glycoprotein in the closed conformation, showing it maintains structure and antigenicity while being applicable to other beta-coronaviruses.

Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2.

This study develops two neutralization assays for SARS-CoV-2 using VSV and a clinical isolate, showing high concordance between monoclonal, polyclonal antibodies, and ACE2-Fc in neutralizing activity.

Structural and functional analysis of a potent sarbecovirus neutralizing antibody

This study identifies and characterizes a potent neutralizing antibody, S309, against SARS-CoV-2 and related sarbecoviruses, showing its efficacy in preventing viral entry and potential for therapeutic use.

Development and use of Lentiviral Vectors Pseudotyped with Influenza B Haemagglutinins: application to vaccine immunogenicity, mAb potency and sero-surveillance studies

The paper develops influenza B haemagglutinin-pseudotyped lentiviral vectors as sensitive tools for detecting neutralizing and cross-reactive antibodies in vaccine and sero-surveillance studies.